Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19,270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: suzuki k. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T. Imai H, et al. Among authors: suzuki k. Lung Cancer. 2018 Dec;126:41-47. doi: 10.1016/j.lungcan.2018.10.014. Epub 2018 Oct 13. Lung Cancer. 2018. PMID: 30527191 Clinical Trial.
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Imai H, et al. Among authors: suzuki k. J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18. J Cancer Res Clin Oncol. 2020. PMID: 31853661
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Imai H, Minemura H, Kishikawa T, Yamada Y, Suzuki K, Umeda Y, Wasamoto S, Kasahara N, Ishihara S, Yamaguchi O, Naruse I, Uchino J, Mori K, Kanazawa K, Shibata Y, Kasai T, Kaburagi T, Kaira K, Minato K. Imai H, et al. Among authors: suzuki k. Thorac Cancer. 2020 Oct;11(10):2867-2876. doi: 10.1111/1759-7714.13622. Epub 2020 Aug 26. Thorac Cancer. 2020. PMID: 32844570 Free PMC article.
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N. Ito K, et al. Among authors: suzuki k. Eur J Cancer. 2021 Mar;145:183-193. doi: 10.1016/j.ejca.2020.12.026. Epub 2021 Jan 22. Eur J Cancer. 2021. PMID: 33486442
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancer.
Tsuda T, Suzuki K, Inomata M, Hayashi K, Mizushima I, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Masaki Y, Taniguchi H, Tobe K. Tsuda T, et al. Among authors: suzuki k. Mol Clin Oncol. 2023 Mar 17;18(5):38. doi: 10.3892/mco.2023.2634. eCollection 2023 May. Mol Clin Oncol. 2023. PMID: 37035471 Free PMC article.
Usefulness of the Palliative Prognostic Index in patients with lung cancer.
Inomata M, Hayashi R, Tokui K, Taka C, Okazawa S, Kambara K, Ichikawa T, Suzuki K, Yamada T, Miwa T, Kashii T, Matsui S, Tobe K. Inomata M, et al. Among authors: suzuki k. Med Oncol. 2014 Sep;31(9):154. doi: 10.1007/s12032-014-0154-x. Epub 2014 Aug 10. Med Oncol. 2014. PMID: 25108600
19,270 results
You have reached the last available page of results. Please see the User Guide for more information.